Margaret Woo

Margaret Woo has a strong background in regulatory affairs and quality, with experience in various roles and companies. Margaret'smost recent position was as Vice President and Head of Regulatory Affairs and Quality at Scorpion Therapeutics since October 2022. Prior to that, they held the role of Vice President and Head of Regulatory Affairs at C4 Therapeutics, Inc. from February 2021 to September 2022. Margaret also worked at the Healthcare Business of Merck, where they served as Senior Director of Global Regulatory Affairs, Oncology from June 2019 to February 2021, and as Director of Global Regulatory Affairs from October 2015 to June 2019. Margaret was a Drug Regulatory Affairs professional at Novartis Oncology from October 2012 to September 2015. Margaret obtained their MS in Bioscience Regulatory Affairs from Johns Hopkins University from June 2011 to May 2013. Prior to that, they worked at Novartis, where they held the positions of Director of Clinical Pharmacology from January 2011 to October 2012, and Clinical Pharmacology Expert (CPE) from March 2003 to December 2010. Margaret's early experience includes a role as a Postdoctoral Research Associate at Washington University School of Medicine in St. Louis from January 2001 to February 2003, and as a Post-doc at St. Jude Children's Research Hospital - ALSAC from 2000 to 2002.

Margaret Woo has a BA in Molecular Cell Biology from the University of California, Berkeley. Margaret also holds a PharmD in Pharmaceutical Sciences from the University of Southern California. In addition to their degrees, Margaret has obtained certifications in Regulatory Excellence Leadership Academy (RELA) from McKinsey & Company in 2019, and in the Global Leadership Program and Future is Now (FIN) from the Healthcare Business of Merck in 2019 and 2017 respectively.